Automatic bone scan index for therapy response assessment of radium-223-dichloride (Ra-223) therapy in advanced prostate cancer

被引：0
|
作者：
Sakretz, M. [1 ]
Kurth, J. [1 ]
Schwarzenboeck, S. M. [1 ]
Krause, B. J. [1 ]
Heuschkel, M. [1 ]
机构：
[1] Univ Rostock, Dept Nucl Med, Med Ctr, D-18055 Rostock, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P748
引用
收藏
页码：S699 / S699
页数：1
相关论文
共 50 条
  • [31] Patterns of bone scan and pain response following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC).
    Shantzer, Lindsey
    Ritz, Michala
    Chin, Bennett B.
    Oldan, Jorge
    Anand, Aseem
    Oyekunle, Taofik
    Anand, Monika
    Armstrong, Andrew J.
    George, Daniel J.
    McNamara, Megan Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Sarcopenia assessment in men with metastatic castration-resistant prostate cancer (mCRPC) undergoing radium 223 (Ra223) therapy
    Khan, M.
    Carvajal, J. Briones
    Parshad, S.
    Emmenegger, U.
    ANNALS OF ONCOLOGY, 2020, 31 : S535 - S535
  • [33] UTILIZATION OF RADIUM-223 DICHLORIDE (RA-223) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CANADA: A REAL-WORLD RETROSPECTIVE STUDY
    Lapierre, M.
    Fraelic, A.
    VALUE IN HEALTH, 2016, 19 (03) : A162 - A162
  • [34] Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases
    Nilsson, Sten
    Sartor, A. Oliver
    Bruland, Oyvind S.
    Fang, Fang
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [35] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A-K
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
  • [36] Radium-223(Ra-223) safety and efficacy in prostate cancer with bone metastases: phase 3 ALSYMPCA study findings stratified by age
    Sartor, Oliver
    Coleman, Robert
    Nilsson, Sten
    Heinrich, Daniel
    Staudacher, Karin
    Garcia-Vargas, Jose
    Vogelzang, Nicholas
    BJU INTERNATIONAL, 2013, 112 : 15 - 16
  • [37] Hematologic Safety Profile of Radium-223 Dichloride (Ra-223) From the Phase 3 ALSYMPCA Trial in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases
    Widmark, A.
    Helle, S. I.
    James, N.
    Larsson, A.
    Staudacher, K.
    Haugen, I.
    Garcia-Vargas, J.
    Nilsson, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S189 - S190
  • [38] Quantitative SPECT/CT of bone scans for prediction of response to Radium-223-Dichloride treatment in patients with mCRPC
    Dittmann, Helmut
    Kaltenbach, Sabine
    Kupferschlaeger, Juergen
    la Fougare, Christian
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [39] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A. K.
    Parker, C.
    ONKOLOGIE, 2013, 36 : 17 - 18
  • [40] External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial
    Paganelli, G.
    Rossetti, C.
    Aglietta, M.
    Messina, C.
    Versari, A.
    Michalski, J. M.
    O'Sullivan, J. M.
    Parker, C.
    Garcia-Vargas, J. E.
    Sartor, A.
    Finkelstein, S. E.
    ANNALS OF ONCOLOGY, 2015, 26 : 62 - 62
12345